Tissue Inhibitor of Metalloproteinase-2 Regulates Matrix Metalloproteinase-2-mediated Endothelial Barrier Dysfunction and Breast Cancer Cell Transmigration Through Lung Microvascular Endothelial Cells

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2010 Jun 24

PMID 20571065

Citations 27

Authors

Qiang Shen

Eugene S Lee

Robert L Pitts

Mack H Wu

Sarah Y Yuan

Affiliations

Soon will be listed here.

Abstract

Matrix metalloproteinases (MMP) have been implicated in multiple stages of cancer metastasis. Tissue inhibitor of metalloproteinase-2 (TIMP-2) plays an important role in regulating MMP-2 activity. By forming a ternary complex with pro-MMP-2 and its activator MMP-14 on the cell surface, TIMP-2 can either initiate or restrain the cleavage and subsequent activation of MMP-2. Our recent work has shown that breast cancer cell adhesion to vascular endothelial cells activates endothelial MMP-2, promoting tumor cell transendothelial migration (TEM(E)). However, the mechanism of MMP-2 regulation during TEM(E) remains unclear. In the current study, we present evidence that MMP-14 is expressed in both invasive breast cancer cells (MDA-MB-231 and MDA-MB-436) and lung microvascular endothelial cells (HBMVEC-L), whereas TIMP-2 is exclusively expressed and released from the cancer cells. The tumor cell-derived TIMP-2 was further identified as a major determinant of endothelial MMP-2 activity during tumor cell transmigration in the presence of MMP-14. This response was associated with endothelial barrier dysfunction because coculture of MDA-MB-231 or MDA-MB-436 with HBMVEC-L caused a significant decrease in transendothelial electrical resistance concomitantly with endothelial cell-cell junction disruption and tumor cell transmigration. Knockdown of TIMP-2 or inhibition of TIMP-2/MMP-14 attenuated MMP-2-dependent transendothelial electrical resistance response and TEM(E). These findings suggest a novel interactive role of breast cancer cells and vascular endothelial cells in regulating the TIMP-2/MMP-14/MMP-2 pathway during tumor metastasis.

Citing Articles

Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer.

Shen Q, Murakami K, Sotov V, Butler M, Ohashi P, Reedijk M Sci Adv. 2024; 10(44):eado8275.

PMID: 39475614 PMC: 11524187. DOI: 10.1126/sciadv.ado8275.

The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma.

Moragas N, Fernandez-Nogueira P, Recalde-Percaz L, Inman J, Lopez-Plana A, Bergholtz H Breast Cancer Res. 2024; 26(1):122.

PMID: 39138514 PMC: 11320849. DOI: 10.1186/s13058-024-01871-0.

Short Antiangiogenic MMP-2 Peptide-Decorated Conjugated Linoleic Acid-Coated SPIONs for Targeted Paclitaxel Delivery in an A549 Cell Xenograft Mouse Tumor Model.

Ngema L, Adeyemi S, Marimuthu T, Ubanako P, Ngwa W, Choonara Y ACS Omega. 2024; 9(1):700-713.

PMID: 38222506 PMC: 10785664. DOI: 10.1021/acsomega.3c06489.

Nitric Oxide-Scavenging, Anti-Migration Effects, and Glycosylation Changes after Hemin Treatment of Human Triple-Negative Breast Cancer Cells: A Mechanistic Study.

Alsharabasy A, Aljaabary A, Bohara R, Farras P, Glynn S, Pandit A ACS Pharmacol Transl Sci. 2023; 6(10):1416-1432.

PMID: 37854626 PMC: 10580390. DOI: 10.1021/acsptsci.3c00115.

Imbalance of Pulmonary Microvascular Endothelial Cell-Expression of Metalloproteinases and Their Endogenous Inhibitors Promotes Septic Barrier Dysfunction.

Jayawardena D, Masciantonio M, Wang L, Mehta S, DeGurse N, Pape C Int J Mol Sci. 2023; 24(9).

PMID: 37175585 PMC: 10178398. DOI: 10.3390/ijms24097875.

References

Seiki M . Membrane-type matrix metalloproteinases. APMIS. 1999; 107(1):137-43. DOI: 10.1111/j.1699-0463.1999.tb01536.x. View

Brevig T, Rohrmann J, Riemann H . Oxygen reduces accumulation of type IV collagen in endothelial cell subcellular matrix via oxidative stress. Artif Organs. 2006; 30(12):915-21. DOI: 10.1111/j.1525-1594.2006.00324.x. View

Atkinson S, Crabbe T, Cowell S, WARD R, Butler M, Sato H . Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes. J Biol Chem. 1995; 270(51):30479-85. DOI: 10.1074/jbc.270.51.30479. View

Monaco S, Sparano V, Gioia M, Sbardella D, Pierro D, Marini S . Enzymatic processing of collagen IV by MMP-2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci. 2006; 15(12):2805-15. PMC: 2242443. DOI: 10.1110/ps.062430706. View

Patanaphan V, Salazar O, Risco R . Breast cancer: metastatic patterns and their prognosis. South Med J. 1988; 81(9):1109-12. View

Jardines L, Callans L, Torosian M . Recurrent breast cancer: presentation, diagnosis, and treatment. Semin Oncol. 1993; 20(5):538-47. View

Whittaker M, Floyd C, Brown P, Gearing A . Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev. 2001; 99(9):2735-76. DOI: 10.1021/cr9804543. View

Sun C, Wu M, Guo M, Day M, Lee E, Yuan S . ADAM15 regulates endothelial permeability and neutrophil migration via Src/ERK1/2 signalling. Cardiovasc Res. 2010; 87(2):348-55. PMC: 2895539. DOI: 10.1093/cvr/cvq060. View

Shah F, Shukla S, Shah P, Shukla H, Patel P . Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009; 46(3):194-202. DOI: 10.4103/0019-509X.52953. View

10.

Sparano J, Bernardo P, Stephenson P, Gradishar W, Ingle J, Zucker S . Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004; 22(23):4683-90. DOI: 10.1200/JCO.2004.08.054. View

11.

Chambers A, MacDonald I, Schmidt E, Koop S, Morris V, Khokha R . Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 1995; 14(4):279-301. DOI: 10.1007/BF00690599. View

12.

La Rocca G, Pucci-Minafra I, Marrazzo A, Taormina P, Minafra S . Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004; 90(7):1414-21. PMC: 2409673. DOI: 10.1038/sj.bjc.6601725. View

13.

Simeone A, McMurtry V, Nieves-Alicea R, Saavedra J, Keefer L, Johnson M . TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res. 2008; 10(3):R44. PMC: 2481491. DOI: 10.1186/bcr2095. View

14.

DeClerck Y, Perez N, Shimada H, Boone T, Langley K, Taylor S . Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 1992; 52(3):701-8. View

15.

Shimura Y, Soloway P, Sang Q, Fridman R . Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun. 2001; 281(1):126-30. DOI: 10.1006/bbrc.2001.4323. View

16.

Kumar P, Shen Q, Pivetti C, Lee E, Wu M, Yuan S . Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med. 2009; 11:e19. PMC: 2828491. DOI: 10.1017/S1462399409001112. View

17.

Lafleur M, Tester A, Thompson E . Selective involvement of TIMP-2 in the second activational cleavage of pro-MMP-2: refinement of the pro-MMP-2 activation mechanism. FEBS Lett. 2003; 553(3):457-63. DOI: 10.1016/s0014-5793(03)01094-9. View

18.

Glinskii O, Huxley V, Turk J, Deutscher S, Quinn T, Pienta K . Continuous real time ex vivo epifluorescent video microscopy for the study of metastatic cancer cell interactions with microvascular endothelium. Clin Exp Metastasis. 2003; 20(5):451-8. DOI: 10.1023/a:1025449031136. View

19.

Lafleur M, Handsley M, Edwards D . Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med. 2003; 5(23):1-39. DOI: 10.1017/S1462399403006628. View

20.

Galvez B, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo A . ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol. 2002; 159(3):509-21. PMC: 2173082. DOI: 10.1083/jcb.200205026. View